Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio” or the
“Company”), a clinical-stage biotechnology company developing
next-generation cell and gene therapies using its proprietary Gene
Circuit platform, today announced that it has appointed Fran
Schulz, a highly experienced biotechnology and financial executive,
to the Senti Bio Board of Directors (“Board”).
“We are excited to welcome Fran to the Senti Bio Board of
Directors,” said Timothy Lu, MD, PhD, Chief Executive Officer and
Co-Founder of Senti Bio. “Fran's deep expertise in the life
sciences industry—spanning finance, strategic planning, operations,
and transactions—will be invaluable as we drive growth and
innovation across our pipeline. Fran's track record of working with
life science companies to drive financial and operational success
aligns with our vision for the future, especially as Senti advances
multiple clinical programs. I am confident her leadership will be
instrumental in strengthening our leadership position in developing
next-generation cell and gene therapies with Gene Circuits.”
“I am honored to join the Senti Bio Board and look forward to
collaborating with such an experienced team to advance the
Company’s goals,” said Ms. Schulz. “Senti Bio's commitment to Gene
Circuit technologies as the foundation for developing smarter
medicines is inspiring, and I am eager to contribute to its mission
of creating cell therapies that outsmart complex diseases using
novel and unprecedented approaches."
Concurrently with Ms. Schulz's appointment to the Board, she
will serve as the chairperson of the Board’s Audit Committee. In
conjunction with Ms. Schulz's appointment, Dr. Omid Farokhzad is
departing from the Board. The Company thanks Dr. Farokhzad for his
years of service as a director.
Ms. Schulz was one of the founding members and senior partners
in Ernst & Young’s (“EY”) Life Sciences Practice and has held
various roles at EY over 35 years. While at EY, Ms. Schulz directly
contributed to the growth of EY into a $45B firm recognized on the
Fortune 100 Best Companies to Work For® list 22 years in a row. She
is also qualified to serve as a financial expert under SEC, NYSE
and NASDAQ rules. Ms. Schulz has spent her career working with
large public and emerging private companies throughout the life
sciences industry. She has deep experience guiding companies to
execute a broad range of corporate deals including collaboration
agreements, corporate spin-offs, reorganizations, and mergers and
acquisitions, with personal involvement in over 100 total equity
and debt transactions, raising over $15 billion in aggregate. Ms.
Schulz also has significant experience with the U.S. Securities and
Exchange Commission (“SEC”) and International Financial Reporting
Standards (“IFRS”).
Ms. Schulz currently serves as a Board Member and Audit
Committee Chair of EDAP TMS SA (Nasdaq:EDAP), a global leader in
robotic energy-based therapies and as a Board Member and Audit
Committee Chair of Menlo College. Previously, she served as a Board
Member, Audit Committee Chair and Finance Committee Chair for the
National Board of Women in Bio (2013–2023) as well as a Board
Member and an Audit Committee member for the California Life
Sciences Industry Association. Ms. Schulz is a certified public
accountant (CPA) licensed in California. Ms. Schulz received her
B.S. in Business Administration from Menlo College.
About Senti BioSenti Bio is a clinical-stage
biotechnology company developing a new generation of cell and gene
therapies for patients living with incurable diseases. To achieve
this, Senti Bio is leveraging a synthetic biology platform called
Gene Circuits to create therapies with enhanced precision and
control. These Gene Circuits are designed to precisely kill cancer
cells, spare healthy cells, increase specificity to target cells
and control the expression of drugs even after administration. The
Company’s wholly-owned pipeline includes off-the-shelf CAR-NK
cells, outfitted with Gene Circuits, to target challenging liquid
and solid tumor indications. Senti Bio has also preclinically
demonstrated that its Gene Circuits can function in T cells.
Additionally, Senti Bio has preclinically demonstrated the
potential breadth of Gene Circuits in other cell and gene therapy
modalities, diseases outside of oncology, and continues to advance
these capabilities through partnerships with Roche/Spark
Therapeutics and Bayer/BlueRock Therapeutics.
Forward-Looking StatementsThis press release
and document contain certain statements that are not historical
facts and are considered forward-looking statements within the
meaning of Section 27A of the Securities Act of 1933, as amended,
and Section 21E of the Securities Exchange Act of 1934, as amended.
These forward-looking statements generally are identified by the
words “believe,” “could,” “predict,” “continue,” “ongoing,”
“project,” “expect,” “anticipate,” “estimate,” “intend,”
“strategy,” “future,” “opportunity,” “plan,” “may,” “should,”
“will,” “would,” “will be,” “will continue,” “will likely result,”
“forecast,” “seek,” “target” and similar expressions that predict
or indicate future events or trends or that are not statements of
historical matters. Forward-looking statements are predictions,
projections, and other statements about future events that are
based on current expectations of Senti Bio’s management and
assumptions, whether or not identified in this document, and, as a
result, are subject to risks and uncertainties. Forward-looking
statements include, but are not limited to, expectations regarding
Senti Bio’s growth, strategy, progress and business development.
These forward-looking statements are provided for illustrative
purposes only and are not intended to serve as and must not be
relied on by any investor as, a guarantee, an assurance, a
prediction, or a definitive statement of fact or probability.
Actual events and circumstances are difficult or impossible to
predict and will differ from assumptions. Many actual events and
circumstances are beyond the control of Senti Bio. Many factors
could cause actual future results to differ materially from the
forward-looking statements in this document, including but not
limited to: (i) changes in domestic and foreign business, market,
financial, political and legal conditions, (ii) changes in the
competitive and highly regulated industries in which Senti Bio
operates, variations in operating performance across competitors,
changes in laws and regulations affecting Senti Bio’s business,
(iii) the ability to implement business plans, forecasts and other
expectations, (iv) the risk of downturns and a changing regulatory
landscape in Senti Bio’s highly competitive industry, (v) risks
relating to the uncertainty of any projected financial information
with respect to Senti Bio, (vi) risks related to uncertainty in the
timing or results of Senti Bio’s clinical trial start up, clinical
studies, patient enrollment, and GMP manufacturing startup
activities, (vii) Senti Bio’s dependence on third parties in
connection with clinical trial startup, clinical studies, and GMP
manufacturing activities, (viii) risks related to delays and other
impacts from macroeconomic and geopolitical events, increasing
rates of inflation and rising interest rates on business
operations, (ix) risks related to the timing and utilization of the
grant from CIRM, and (x) the success of any future research and
development efforts by Senti Bio. The foregoing list of factors is
not exhaustive. You should carefully consider the foregoing factors
and the other risks and uncertainties described in the “Risk
Factors” section of Senti Bio’s most recent periodic report filed
with the SEC, and other documents filed by Senti Bio from time to
time with the SEC. These filings identify and address other
important risks and uncertainties that could cause actual events
and results to differ materially from those contained in the
forward-looking statements in this document. There may be
additional risks that Senti Bio does not presently know, or that
Senti Bio currently believes are immaterial that could also cause
actual results to differ from those contained in the
forward-looking statements in this document. Forward-looking
statements speak only as of the date they are made. Senti Bio
anticipates that subsequent events and developments may cause Senti
Bio’s assessments to change. Except as required by law, Senti Bio
assumes no obligation to update publicly any forward-looking
statements, whether as a result of new information, future events,
or otherwise.
Availability of Other Information About Senti
Biosciences, Inc.For more information, please visit the
Senti Bio website at https://www.sentibio.com or follow Senti Bio
on X (formerly Twitter) (@SentiBio) and LinkedIn (Senti
Biosciences). Investors and others should note that we communicate
with our investors and the public using our company website
(www.sentibio.com), including, but not limited to, company
disclosures, investor presentations and FAQs, Securities and
Exchange Commission filings, press releases, public conference call
transcripts and webcast transcripts, as well as on X and LinkedIn.
The information that we post on our website or on X or LinkedIn
could be deemed to be material information. As a result, we
encourage investors, the media and others interested to review the
information that we post there on a regular basis. The contents of
our website or social media shall not be deemed incorporated by
reference in any filing under the Securities Act of 1933, as
amended.
Senti Bio Contacts
Investors: investors@sentibio.com
Media: media@sentibio.com
Senti Biosciences (NASDAQ:SNTI)
Graphique Historique de l'Action
De Nov 2024 à Déc 2024
Senti Biosciences (NASDAQ:SNTI)
Graphique Historique de l'Action
De Déc 2023 à Déc 2024